Quelltext der Seite Alimta price9928400

Pleural mesothelioma patients treated with both cisplatin and raltitrexed may survive longer than patients who receive cisplatin alone, according to a recent 
study conducted in Europe and Canada (J Clin Oncol. 2005 Oct 1; 23(28): 68819). Raltitrexed (Tomudex) works by interfering with the ability of tumor cells to 
multiply and make deoxyribonucleic acid or DNA. Cisplatin is a traditional chemotherapy drug.

Two hundred fifty pleural mesothelioma patients took part in a clinical trial to determine the safety and effectiveness of raltitrexed. One hundred 
twentyfour patients took cisplatin and the rest took cisplatin plus raltitrexed. Most were men with an average age of 58 who had not received other 
chemotherapy treatments.

The raltitrexed study was a phase III clinical trial, as defined by the European Organization for Research and Treatment of Cancer. A phase III trial 
compares a new cancer treatment with a standard treatment, and requires a large number of participants. It follows a phase II clinical trial, which is 
concerned with the safety of a new treatment and how to administer it, and a basic phase I clinical trial, which tests the drugs effectiveness on a small 
number of patients.

Survival Increased in Patients Treated with Raltitrexed 
The researchers looked at survival, progression of pleural mesothelioma, safety, tumor response rates, and the patients quality of life. They found the 
following:
[http://www.avastina.com tarceva]